LAURENCE S. FARER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: I wish to comment on a possible misinterpretation of the data presented by Dr. Zimmerman in the NIH Conference published in the February issue (1). He describes the characteristics of clinically overt hepatic injury in 114 patients reported by Black, Mitchell, and Zimmerman (2), and indicates that 13 of the 114 (12%) died. Most of the 114 cases studied by Black's group came from the U.S. Public Health Service prospective surveillance of 13 838 isoniazid recipients in cities across the United States. However, the authors added 27 other patients, accounting for 6 of the 13 fatalities in
FARER LS. Isoniazid and Liver Injury. Ann Intern Med. ;84:753–754. doi: 10.7326/0003-4819-84-6-753
Download citation file:
Published: Ann Intern Med. 1976;84(6):753-754.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use